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Alarmins in Frozen Shoulder
A Molecular Association Between Inflammation and Pain
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Investigation performed at the University of Glasgow, UK,
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Background: The pathophysiological mechanisms behind proliferation of fibroblasts and deposition of dense collagen matrix in
idiopathic frozen shoulder remain unclear. Alarmins (also known as danger signals) are endogenous molecules that are released
into the extracellular milieu after infection or tissue injury and that signal cell and tissue damage.
Purpose: To investigate whether the presence of alarmins is higher in patients with idiopathic frozen shoulder than in control
subjects.
Study Design: Controlled laboratory study.
Methods: Shoulder capsule samples were collected from 10 patients with idiopathic frozen shoulder and 10 patients with unsta-
ble shoulders (control). The samples were stained with hematoxylin and eosin (H&E) and analyzed by immunohistochemistry using
antibodies against alarmin molecules including high-mobility group protein B1 (HMGB1), interleukin 33, S100A8, S100A9, and the
peripheral nerve marker PGP9.5. Immunoreactivities were rated in a blinded fashion from ‘‘none’’ to ‘‘strong.’’ Immunohistochem-
ical distribution within the capsule was noted. Before surgery, patient-ranked pain frequency, severity and stiffness, and the range
of passive shoulder motion were recorded and statistically analyzed.
Results: Compared with control patients, patients with frozen shoulder had greater frequency and severity of self-reported pain
(P = .02) and more restricted range of motion in all planes (P\ .05). H&E-stained capsular tissue from frozen shoulder showed
fibroblastic hypercellularity and increased subsynovial vascularity. Immunoreactivity of alarmins was significantly stronger in fro-
zen shoulder capsules compared with control capsules (P\ .05). Furthermore, the expression of the alarmin molecule HMGB1
significantly correlated (r. 0.9, P\ .05) with frequency of severity of pain and extreme pain in patients with frozen shoulder com-
pared with controls.
Conclusion: This study demonstrates a potential role for key molecular danger signals in frozen shoulder and suggests an asso-
ciation between the expression of danger molecules and the pain experienced by patients.
Keywords: frozen shoulder; alarmins; inflammation; pain; HMGB1; adhesive capsulitis; IL-33; S100
Adhesive capsulitis or frozen shoulder is defined as a clini-
cal condition restricting the passive and active movement
of the shoulder joint in all directions, including flexion,
abduction, and rotation.5 Frozen shoulder is the third
most common cause of musculoskeletal disability in the
United States and is more common in the fifth and sixth
decades of life, affecting women more than men.22 Cases
of frozen shoulder are typically categorized into 3 groups:
idiopathic, primary, and secondary. Primary adhesive cap-
sulitis is normally idiopathic but has associations with
hyperthyroidism, hypothyroidism, diabetes, and Dupuy-
tren disease, while secondary adhesive capsulitis is usually
the sequela of previous trauma, including surgery or
immobilization.18
Our current understanding of the underlying cause and
pathogenesis of frozen shoulder remains limited. Histologic
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studies have demonstrated fibroblastic and myofibroblastic
proliferation in dense type I and III collagen matrix in the
shoulder capsule, while capsular fibrosis and contracture
have been suggested to stiffen the shoulder capsule and
thus restrict range of motion.5 Histologically, frozen shoul-
der tissue is characterized by myofibroblasts and chronic
inflammatory cells, including mast cell, T cells, B cells,
and macrophages.4,16 Furthermore, cytokines such as
interleukin 1b (IL-1b), interleukin 6 (IL-6), and tumor
necrosis factor a (TNF-a), which are known to drive
inflammatory and matrix interactions37 including fibro-
blast activation and dysregulated collagen synthesis, are
upregulated in adhesive capsulitis versus normal shoulder
capsule45 and the subacromial bursa28 of patients with fro-
zen shoulder. The clinical picture of significant shoulder
pain has also been linked to increased cytokine produc-
tion,20 while several studies highlighted increased nerve
ingrowth52 and neuronal mediators in frozen shoulder.16,49
Alarmins (also known as danger signals) are endoge-
nous molecules that are released into the extracellular
milieu after infection or tissue injury and that signal cell
and tissue damage.3 These molecules have been shown to
be associated with cytokine activation and the influx of
immune cells such as monocytes.36 Alarmins share com-
mon functional characteristics; in addition to causing
immune cell activation, alarmins are released rapidly dur-
ing necrosis and apoptosis while retaining the potential for
active secretion by immune cells and ultimately promoting
tissue homeostasis40; thus, modulating their activity may
provide novel avenues to control a variety of inflammatory
processes. It is now widely accepted that alarmins play
a key role in the pathogenesis of many inflammatory dis-
eases and not only initiate but amplify and sustain the
inflammatory processes. The best characterized alarmins
in musculoskeletal disease are high-mobility group protein
B1 (HMGB1), S100 proteins (S100A8 and S100A9), heat
shock proteins (HSPs), and interleukin 33 (IL-33). Ele-
vated serum levels and expression of S100 proteins within
inflamed synovium have been reported in rheumatoid
arthritis,11 psoriatic arthritis,21 and spondylarthropathy.23
HMGB1 is expressed in synovial fluid and serum of
patients with rheumatoid arthritis,15 while therapeutic
blockade of HMGB1 prevents progression in mouse models
of arthritis.31 Additionally, we have shown that IL-33 is an
alarmin in early tendinopathy34 with the ability to modu-
late inflammatory and matrix crosstalk and thus is likely
to be important in the balance between reparation and
degeneration in tissue repair.
To our knowledge, no previous studies have considered
the potential contribution of alarmins in frozen shoulder.
Thus, given the potential role of alarmins in soft tissue
immunobiology, we designed a study to investigate
whether alarmins might contribute to the pathogenic
mechanisms of frozen shoulder. The aims of this study
were to evaluate alarmin molecules in patients presenting
with frozen shoulder and to assess any correlation of these
molecules with patient symptoms.
METHODS
Study Design
A prospective case-control study was conducted at the Ortho-
paedic Research Institute, St George Hospital, Sydney, NSW,
Australia, and the Institute of Infection, Immunity and
Inflammation at the University of Glasgow, Scotland, UK.
The study was conducted in accordance with ethics approval
from Human Research Ethics Committee–Central Network,
South East Health (HREC/96/55, HREC/14/130) and West
of Scotland REC (REC14/WS/1035).
Inclusion and Exclusion Criteria
The study included patients with primary frozen shoulders
who were receiving arthroscopic capsular releases. It also
included a control group of patients with unstable should-
ers undergoing arthroscopic stabilization; these patients
were thought not to have primary shoulder disease affect-
ing the shoulder capsule and they required glenohumeral
arthroscopy, which was necessary to obtain tissue samples.
The diagnosis of frozen shoulder was made by use of
Codman’s modified criteria by Zuckerman and Rokito.54
The inclusion criteria for the frozen shoulder population com-
prised a painful stiff shoulder with insidious onset, elevation
restricted to 100 or less, passive external rotation 50% or
less of the normal contralateral shoulder, loss of function of
the affected arm, pain at night and inability to lie on the
affected side, and unremarkable radiographic and ultrasono-
graphic findings of the glenohumeral joint. The exclusion cri-
teria included previous surgery of the involved shoulder and
radiologic or arthroscopic signs of fracture, glenohumeral
arthritis, history of shoulder trauma, and concomitant rota-
tor cuff tear.
Sample Collection
Tissue specimens were excised from the shoulder capsule
by the same surgeons (G.A.C.M., N.L.M.) during gleno-
humeral joint arthroscopy in patients undergoing either
arthroscopic capsular release or stabilization surgery as
previously described.19 The tissue was removed by menis-
cal basket forceps from the shoulder capsule of the rotator
interval. The biopsied tissue was immediately fixed in 10%
buffered formalin for 18 to 24 hours, dehydrated, and
embedded in paraffin wax.
Pain and Stiffness Scores
On their first visit to the shoulder clinic, patients completed
a modified L’Insalata questionnaire form,25 which recorded
subjective experience of pain frequency, pain severity, and
stiffness. Patients answered questions regarding frequency
of activity pain, night pain and extreme pain, severity of
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resting pain, activity pain and night pain, and shoulder
stiffness. Pain frequency was ranked by use of Likert scales
as never (0), sometimes (1), monthly (2), weekly (3) or daily
(4). Pain severity and stiffness were ranked as none (0), mild
(1), moderate (2), severe (3), or very severe (4). The patient-
ranked pain frequency and severity scores were summed to
a maximum score of 12. The maximum patient-ranked stiff-
ness was 4.
Immunohistochemistry
Samples for immunohistochemistry were immediately fixed
in 10% formalin solution and stained with hematoxylin and
eosin (H&E). Ten unstained sections were immunostained
for the alarmin molecules IL-33 (Nessy-1, ALX-804-840-
C100; Enzo Lifesciences), HMGB1 (Cambridge Bioscience),
S100A8 (Abnova MAB7961), and S100A9 (Abnova PAB11
470). Additionally, we used PGP9.5 (polyclonal rabbit anti-
PGP9.5; Invitrogen) as a peripheral nerve marker, CD68
as a macrophage marker, and mast cell tryptase as a mast
cell marker on the same 10 unstained samples. The
unstained sections were dewaxed in an oven at 60C for
35 minutes. They were then immersed in 2 changes of
xylene for 5 minutes each and deparaffinated in 100%,
90%, and 70% ethanol solution for 2 cycles of 3 minutes
each; thereafter, they were rehydrated in distilled water
for 5 minutes. Sections were then immersed in 0.5% hydro-
gen peroxide made up in methanol for 30 minutes to block
endogenous peroxidase activity and then tris-buffered
Saline 0.05% with Tween (TBST) solution (pH 7.6). Endog-
enous peroxidase activity was quenched with 3% (vol/vol)
H2O2, and nonspecific antibody binding was blocked with
2.5% horse serum in TBST buffer for 30 minutes. Antigen
retrieval was performed in 0.01 M citrate buffer for 20
minutes in a microwave. After excess solution was removed,
IL-33, HMGB1, S100A8, S100A9, and PGP9.5 antibodies
were added at 5 mg/mL, 2 mg/mL, 3 mg/mL (S100A8 and
A9), and 1 in 1000 dilution, respectively; dilutions were
made up with 2.5% normal horse serum. The sections
were left overnight to incubate at 4C.
The sections were brought to room temperature for 30
minutes and washed in TBST solution for 5 minutes. The
sections were then incubated in 3,3#-diaminobenzidine
(DAB) solution (1 drop of DAB to 1 mL of DAB diluent)
for 30 seconds and quickly washed with TBST solution.
They were then dipped twice in hematoxylin, washed in
water, dipped in Scott’s solution to blue, and then dehy-
drated in 70% ethanol (30 seconds), 90% ethanol (1 min-
ute), and 2 changes of 3 minutes in 100% ethanol. Then
the sections were cleared in 2 changes of xylene for 3
minutes and mounted in DPX with a coverslip.
Microscopic Analysis
Tissue sections were examined under light microscopy at
3100 and 3400 magnifications and compared with the neg-
ative controls. Representative photomicrographs of the sec-
tions in each group were made. Two experienced examiners
(J.C., N.L.M.) blinded to the identity of the stained sections
performed the counting of each section.
Tissue analysis occurred in 2 stages. In the first stage,
all samples were given a semiquantitative grade based
on the percentage of positively stained cells (taken over
the total number of cells in that field) in 10 random high-
power fields. The following semiquantitative scoring (mod-
ified Bonar score) was used: grade 0, no staining; grade 1,
mild, \10% of cells stained positive; grade 2, moderate,
10% to 20% of cells stained positive; grade 3, strong,
.20% of cells stained positive. The mean of these values
was analyzed by an unpaired Student t test.
In the second stage, 10 random high-power fields of the
samples were analyzed at 340 magnification, and cells in
each field were counted manually. The mean percentage
of positively stained cells was taken over the total number
of cells per high-power field; similarly, the results were
analyzed by an unpaired Student t test.
Statistical Analysis
Results are reported as the mean value and the standard
error of mean. Comparisons between groups were made
with 2-way paired Student t tests, Mann-Whitney U tests,
and Kruskal-Wallis 1-way analysis of variance on ranks.
On the basis of our previous immunohistochemical stud-
ies35 and power calculations7,38 (power of 0.8 and beta
error of 0.2), we identified that each group required 10
patient samples to detect a 20% difference in immunostain-
ing for the various alarmin markers. Correlations were cal-
culated with the Pearson coefficient.
RESULTS
Demographics
The samples of a total of 20 patients were included in the
study. Of these 20 patients, 10 had adhesive capsulitis (5
females, 5 males; mean age 54 years; range, 42-65 years)
and 10 had shoulder instability (2 females, 8 males;
mean age 33 years; range, 18-46 years). The instability
group was significantly younger than adhesive capsulitis
group (P\ .01). The mean number of glenohumeral joint
injections was significantly (P\ .05) greater in the frozen
shoulder group compared with control (Table 1).
Pain and Stiffness Scores
Patient-ranked pain frequency (P = .02), pain severity (P =
.02), and stiffness (P = .04) were significantly higher in the
frozen shoulder group compared with the instability group
(Figure 1). Shoulder motion was also significantly more
restricted in external rotation, internal rotation, forward
flexion, and abduction in patients with frozen shoulder
compared with the instability group (Table 1).
Histologic Appearance of the Shoulder Capsule
The histologic appearance of the H&E-stained frozen shoul-
der capsule specimens showed densely packed collagen fibers
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and fibroblastic proliferation within the fibrous stroma com-
pared with the controls (Figure 2A). Large numbers of capil-
laries and venules were seen in the subsynovium of frozen
shoulder samples compared with the controls. Capsule speci-
mens from 4 instability patients also exhibited few capillaries
and venules in the subsynovium, whereas 2 had increased
vascularity.
Increased Alarmin Expression and
Neoinnervation in Adhesive Capsulitis
Significantly greater expression of the alarmin molecules
HMGB1, IL-33, S100A8, and S100A9 was seen in the fro-
zen shoulder group compared with the control group (P\
.05) (Figure 2B). HMGB1 and IL-33 were mainly localized
to stromal cells, while the S100 molecules were less abun-
dant and wholly localized to immune cells (Figure 2B).
Further subanalysis of tissue distribution revealed that
HMGB1 was most abundantly expressed in adhesive cap-
sulitis with approximately 50% of cells positive versus
26% in control tissues (Figure 3), followed by IL-33 (25%
vs 14% control, P\ .05). In keeping with the localization
of the S100 proteins to immune cells, only 4% of cells
were positive for S100A8 versus 1% in control tissues
(P \ .05) and 5% were positive for S100A9 versus 1% in
control tissues (P \ .05) (Figure 3). Further subanalysis
using back-to-back staining with the macrophage marker
CD68 revealed that both S100A8 and S100A9 were local-
ized to macrophage cells.
Neoinnervation and HMGB1 Expression
Correlate to Patient Pain
Patients with frozen shoulder had significantly greater
neoinnervation (P\ .01) compared with the control group
(Figures 2 and 3). Increased neoinnervation positively cor-
related with the frequency of severity of pain (r = 0.99, P\
.05) and extreme pain (r = 0.93, P\ .05) in patients with
frozen shoulder versus control patients (Figure 4B).
Increased HMGB1 expression positively correlated with
the frequency of night pain (r = 0.97, P\ .05) and extreme
pain (r = 0.96, P \ .05) in patients with frozen shoulder
versus control patients (Figure 4A). We found no correla-
tion between alarmin tissue staining and the number of
steroid injections (r = 0.2, P = .8) preoperatively or coexist-
ing metabolic issues (diabetes or thyroid disease; r = 0.01,
P = .7).
Figure 1. (A) Patient-ranked shoulder pain frequency, pain
severity, and stiffness scores in patients with frozen shoulder
(n = 10) compared with those with instability (n = 10). Data
show mean with the standard error of the mean (error
bars). *P \ .05, Kruskal-Wallis-Dunn multiple comparisons
test. (B) Patient demographics and shoulder range of motion
in patients with frozen shoulder (n = 10) compared with those
with instability (n = 10).[AQ: 1]
TABLE 1
Patient Demographics
Adhesive Capsulitis
(Frozen Shoulder)
Instability
(Controls)
No. of patients 10 10
Age, mean (range), y 54 (42-65) 33 (18-46)
Sex, female:male, n 5:5 2:8
Duration of symptoms,
mean 6 SEM, mo
6.3 6 3 3.9 6 2
Range of motion,
mean 6 SEM, deg
Forward flexion 80 6 12 160 6 8
Abduction 62 6 10 145 6 10
External rotation 11 6 5 60 6 15
No. of steroid injections
before surgery, mean 6 SEM
1.6 6 0.2 0.4 6 0.1
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DISCUSSION
This study, which is the first to investigate the expression of
alarmin molecules in frozen shoulder capsule, has demon-
strated the presence of HMGB1, IL-33, S100A8, and
S100A9 in shoulder capsule tissue of patients with adhesive
capsulitis. Furthermore, we demonstrate that patient-
reported pain in frozen shoulder directly correlates with
increased neoinnervation and HMGB1 expression.
HMGB1 is a nuclear protein released in nonprogrammed
cell death and secreted by immune46 and stromal cells,
including fibroblasts.29,42 As well, HMGB1 can be induced
by damage-associated molecular patterns (DAMPs), cyto-
kines, and certain states of cellular stress.36 Conditions asso-
ciated with an increase in HMGB1 include rheumatoid
arthritis, systemic lupus erythematosus, and Sjo¨gren syn-
drome,36 whereas exposure of synovial fluid macrophages to
HMGB1 results in the release of proinflammatory cytokines
such as TNF-a, IL-1b, and IL-6.26,27,48 In particular,
HMGB1 acts as a DAMP after its release6,32 upon stress con-
ditions, which, in turn, are considered crucial to the onset and
perpetuation of frozen shoulder.44,17 Thus, our results demon-
strating significantly increased HMGB1 expression localized
Figure 2. (A) Hematoxylin and eosin (H&E) sections from fro-
zen shoulder showing310 and340 representative images of
frozen shoulder tissue. (B) Immunostaining for the alarmins
high-mobility group protein B1 (HMGB1), interleukin 33 (IL-
33), S100A8, and S100A9 and peripheral nerve (PGP9.5)
markers in frozen shoulder compared with control. All slides
represent 3200 magnification, and isotype controls (immu-
noglobulin G) are shown in the bottom right corner of the fro-
zen shoulder images.
Figure 3. (A) Graph illustrating modified Bonar score for
samples of human frozen shoulder for expression of high-
mobility group protein B1 (HMGB1), interleukin 33 (IL-33),
S100A8, S100A9, and PGP9.5 markers, with mean and
SEM shown. n = 10 for frozen shoulder, n = 10 for instability
control. Modified Bonar scoring system depicts mean score
per sample based on 10 high-power fields. 0 = no staining;
1 =\10%; 2 = 10%-20%; and 3 = .20% positive staining
of cells per high-power field. *P\ .05, **P\ .01 (Student
t test). (B) Quantitative expression of HMGB1, IL-33,
S100A8, S100A9, and PGP9.5 depicting mean cells per sam-
ple based on 10 high-power fields. n = 10 for frozen shoul-
der, n = 10 for instability control capsule (Student t test).
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to stromal cells in frozen shoulder suggest that the resident
stromal cells (fibroblasts and endothelial cells) may act as
damage-sensing cells that release HMGB1 upon stress, per-
petuating the inflammatory tissue response seen in patients.
Moreover, agents targeting HMGB1 have delivered promis-
ing in vitro and in vivo data,10,39,47 particularly altering
matrix regulation, suggesting that HMGB1 may offer thera-
peutic utility by providing a novel pathway to target in frozen
shoulder.
Recently, HMGB1 was shown to be secreted not only by
leukocytes and stromal cells but also by irritated or dam-
aged neurons, which release HMGB1 into the extracellu-
lar space.50 Experimental studies suggest that HMGB1 is
released both peripherally and spinally in models of path-
ologic pain and can drive nociceptive signaling via actions
on sensory neuronal and immune cells.1 Of importance,
systemic and intrathecal administration of HMGB1-
blocking agents reverses pain-like behavior, indicating
that HMGB1 has pronociceptive properties in both the
peripheral and central nervous systems.51 Our data
suggest that increased expression of HMGB1 is directly
associated with increased patient-reported pain and as
such may be a molecular mediator of the significant
pain associated with frozen shoulder. More studies are
now required to elucidate the underlying mechanisms
involving HMGB1 upregulation to understand whether
this danger signal is involved in shoulder inflammation
and pain in patients with frozen shoulder. Additionally,
our results suggest that HMGB1 may be a promising bio-
marker for frozen shoulder diagnosis and patient out-
comes. We have previously used PGP9.5 as a peripheral
nerve marker to quantify the degree of neoinnervation
in soft tissue disorders such as frozen shoulder19 and cal-
cific tendinopathy14 and link its expression to patient-
reported pain. Our results in this cohort of patients fur-
ther suggest that the significant pain associated with fro-
zen shoulder is linked to increased peripheral nerve
ingrowth. Future work should therefore explore the
molecular mechanisms involved in neoinnervation and
inflammation in frozen shoulder.
Figure 4. (A) High-mobility group protein B1 (HMGB1) and (B) PGP9.5 count per high-power field (HPF) correlated with patient-
reported frequency of night pain and frequency of extreme pain in patients with frozen shoulder versus control as shown by the
indicated Pearson coefficient.
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IL-33 induces hematopoietic cells such as macrophages,
mast cells, and neutrophils to produce cytokines such as
IL-6, TNF-a, and IL-1b. IL-33 has also been shown to
increase vascular permeability and to induce chemotaxis,
angiogenesis, and endothelial cell activation.2,9 Moreover
elevated serum IL-33 has been found in autoimmune mus-
culoskeletal diseases41 and fibrotic conditions such as sys-
temic sclerosis and liver fibrosis,33,43,53 suggesting that
while IL-33 promotes tissue repair, there is evidence of
maladaptation resulting in pathologic changes and fibro-
sis.30 We have previously shown that IL-33 is mainly
expressed in the stromal tissue compartment in tendinop-
athy and is crucial in driving inflammatory and matrix
changes toward degenerative disease.34 Our finding of ele-
vated nuclear expression of IL-33 in frozen shoulder stro-
mal cells is therefore likely to signify that IL-33 is
involved in the key pathologic features of angiogenesis
and capsular tissue fibrosis. Furthermore, given the role
of IL-33 in immune cell recruitment and activation,24 par-
ticularly macrophages and mast cells, which are found in
abundance in human frozen shoulder biopsy specimens,16
IL-33 may be an important immune cell coordinator driv-
ing the inflammatory component of the frozen shoulder.
In contrast, S100A8 and S100A9 are expressed to
a much lesser extent in frozen shoulder and are localized
around immune cells under histologic analysis. S100A8
and S100A9 were initially identified in the context of rheu-
matoid arthritis,12 with activated phagocytes expressing
these S100 proteins in the inflammatory lesions in syno-
vium.13 In patients with active disease, S100A8 and
S100A9 were expressed in macrophage-like cells within
the lining layer, showing altered activation and differenti-
ation.8 In view of this, we carried out further immunostain-
ing with a macrophage marker in a subgroup of patients
with frozen shoulder, which revealed that the S100 protein
expression was localized to macrophages. Thus, in frozen
shoulder it appears that the S100 proteins are upregulated
in macrophages and are therefore likely to be involved in
macrophage differentiation and recruitment, further sup-
porting the concept that frozen shoulder has a strong
inflammatory and immunological origin.
Our study has inherent limitations. The sample size
was small; however, our previous studies14,19,38 and power
analysis confirmed that 10 patient samples per group were
sufficient, which gives us confidence that the changes seen
represent a biologically relevant change in protein expres-
sion. Additionally, a selection bias was present in that we
studied only patients with frozen shoulder that warranted
a surgical procedure, and thus we did not include asymp-
tomatic patients or patients who had less intense pain
with frozen shoulder. Furthermore, the patients in the con-
trol group were younger, were predominately male, and
had shorter duration of symptoms compared with the fro-
zen shoulder group, which is an unfortunate consequence
of the availability of human control tissues. Two surgeons
were involved in the collection of samples, giving rise to the
possibility that surgical technique and biopsies had some
user-related differences. Despite this, the same method of
obtaining samples was used to reduce the surgeon-related
bias. This study ensured that comparison occurred only
between shoulder capsule samples of patients with adhe-
sive capsulitis and shoulder capsules samples of patients
with instability. This allowed a comparison between the
same type of tissue and removed the possibility that path-
ologic abnormalities in other tissue types, such as tendons,
could confound the study. The exclusion of patients with
concurrent pathologic conditions such as osteoarthritis
and rheumatoid arthritis also allowed better isolation of
cases to adhesive capsulitis in the shoulder. As such,
results of immunoreactivity were less likely to be affected
by other comorbidities.
CONCLUSION
This study has shown for the first time that the alarmins
HMGB1, IL-33, S100A8, and S100A9 are elevated in the
shoulder capsule of patients with frozen shoulder compared
with controls while furthermore confirming significantly
increased neoinnervation linked to patient-reported pain.
These data are consistent with the hypothesis that alarmins
play a role in frozen shoulder and could explain the cellular
mechanisms behind capsular fibrosis and nerve growth.
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